# **RSC Advances**



View Article Online

View Journal | View Issue

## PAPER

Check for updates

Cite this: RSC Adv., 2018, 8, 11061

Received 1st March 2018 Accepted 9th March 2018 DOI: 10.1039/c8ra01806e rsc.li/rsc-advances

### 1. Introduction

CXCR1 and CXCR2 are CXC chemokine receptors (CXCRs) and G-protein coupled receptors, which correspond to cytokines of the CXC chemokine family. CXCR2 was found to be 77% homologous to CXCR1.<sup>1,2</sup> The CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) can both be activated by chemokine CXCL8 (interleukin-8, IL-8) and granulocyte chemotactic protein-2. Furthermore, CXCR2 can also be activated by several other ELR<sup>+</sup> CXC chemokines, including neutrophil-activating peptides and growth related oncogenes (GRO $\alpha$ ,  $\beta$  and  $\gamma$ ).<sup>3</sup> Several studies have demonstrated the intimate relationship between CXCR2 and different cancer types.<sup>4-9</sup> Here, the blockade of CXCR2 represents an attractive strategy for the treatment of cancer metastasis.<sup>5,7,10-19</sup> As shown in Fig. 1, CXCR1 or CXCR2

## Bicyclo[2.2.1]heptane containing *N*,*N*<sup>'</sup>diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents<sup>†</sup>

Jin-Xin Che,<sup>a</sup> Zhi-Long Wang,<sup>b</sup> Xiao-Wu Dong, <sup>b</sup> You-Hong Hu, <sup>b</sup> Xin Xie<sup>\*bc</sup> and Yong-Zhou Hu<sup>\*a</sup>

CXCR1 and CXCR2 are CXC chemokine receptors (CXCRs), corresponding to cytokines of the CXC chemokine family. CXCR2 was found to be 77% homologous to CXCR1. Antagonism of the chemokine receptor CXCR2 has been proposed as a new strategy for the treatment of metastatic cancer. In order to find a CXCR2 selective antagonist, a bicyclo[2.2.1]heptane containing *N*,*N'*-diarylsquaramide (compound **2e**) was identified by introducing a bridge ring system into the *N*,*N'*-diarylsquaramide skeleton, and it exhibited good CXCR2 antagonistic activity ( $^{CXCR2}IC_{50} = 48$  nM) and good selectivity ( $^{CXCR2}IC_{50} = 60.4$ ). Furthermore, an *in vitro* biological assay of compound **2e** also demonstrated its good anti-cancer metastatic effect against the pancreatic cancer cell line CFPAC1. In addition, compound **2e** showed an extremely high stability in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF), as well as in rat and human plasma, but not in rat and human liver microsomes. *In vivo* pharmacokinetic studies in rats indicated that **2e** has an excellent PK profile (10 mg kg<sup>-1</sup> po,  $C_{max} = 2863$  ng mL<sup>-1</sup>,  $t_{1/2} = 2.58$  h). Moreover, molecular docking was further implemented to propose the preponderant configuration of compound **2e**, providing important and useful guidelines for further development.

antagonists such as **AZD5069**, **Danirixin**, **Reparixin**, **Ladarixin** and **SX-682** have entered clinical trials for different indications. Among these compounds, the CXCR2 selective antagonist **AZD5069** is currently in phase II clinical trials for the treatment of metastatic head & neck cancer and metastatic pancreatic cancer, administered in combination with **MEDI4736** (a PD-L1 inhibitor). In addition, **SX-682** is also in phase I clinical trials for the treatment of metastatic melanoma, in combination with pembrolizumab. Therefore, developing novel CXCR2 selective antagonists may provide inspiration in future studies.

Among numerous structural motifs in clinical compounds, polycyclic hydrocarbon scaffolds offer a variety of diverse features such as a unique three-dimensional shape and hydrophobic and pharmacokinetic properties.<sup>20-23</sup> As shown in Fig. 2(A), the use of bicyclic motifs of polycyclic scaffolds, including bicyclo[2.2.1], bicyclo[2.2.2], bicyclo[4.4.1] and bicyclo[5.3.1], appears to be a widely used strategy in drug discovery.<sup>20</sup> Furthermore, it is obvious that bridge ring systems play an important role in various pharmaceutical compounds.

The *N*,*N*<sup>'</sup>-diarylsquaramide CXCR1/2 antagonist **MK7123** (**SCH527123**) has been discontinued in phase II clinical trials. The indications of **MK7123** were chronic obstructive pulmonary disease (COPD), asthma and psoriasis. **MK7123** exhibited 10-fold greater selectivity for CXCR1 over CXCR2.<sup>24</sup> As shown in

<sup>&</sup>quot;ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, PR China. E-mail: huyz@zju.edu.cn

<sup>&</sup>lt;sup>b</sup>State Key Laborarory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China

<sup>&</sup>lt;sup>c</sup>CAS Key Laboratory of Receptor Research, The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China. E-mail: xxie@mail.shcnc.ac.cn

 $<sup>\</sup>dagger$  Electronic supplementary information (ESI) available: CXCR2 homologous modeling,  $^{\rm CXCR1/2} \rm IC_{50}$  curve graphs, and NMR spectra of compounds 1a and 2e. See DOI: 10.1039/c8ra01806e





Fig. 1 Structures of clinical compounds.



Fig. 2 (A) Drugs containing bridge ring systems; (B) the right and lefthand parts of MK7123; (C) compound design rationale.

Fig. 2(B), due to the high tolerance and hydrophobic characteristics of the right-hand part of the compound,<sup>24-26</sup> polycyclic hydrocarbon scaffolds were introduced to explore the CXCR2 selectivity and anti-cancer metastatic effect.

At first, a simple bicyclo[2.2.1] moiety was introduced to afford compound **1a**, as shown in Fig. 2(C). Interestingly, compound **1a** showed a 113-fold selectivity for CXCR2 over CXCR1 (<sup>CXCR1</sup>IC<sub>50</sub> = 7  $\mu$ M, <sup>CXCR2</sup>IC<sub>50</sub> = 0.062  $\mu$ M). In order to develop CXCR2 selective antagonists with much higher antagonistic potentials, promising pharmacokinetic profiles and good anti-cancer metastasis effects, other bridge ring systems were considered. Meanwhile, the introduction of different electron-withdrawing groups to the left-hand part of the structure was also evaluated.

## 2. Results and discussion

#### 2.1 Chemistry

The synthesis of target compounds 1a-1f is illustrated in Scheme 1. The substituted aminophenol (compound 6) was derived from a commercially available starting material (3-nitrosalicylic acid 3). The acyl chloride containing compound 4 was obtained *via* an acylation reaction with thionyl chloride, and successive condensation in the presence of dimethylamine hydrochloride afforded the amide compound 5. Subsequently, the aniline compound 6 was acquired *via* reduction of the nitrocontaining compound 5 in a H<sub>2</sub> Pd/C system. After this, compound 6 underwent a nucleophilic substitution reaction with 3,4-diethoxycyclobut-3-ene-1,2-dione to provide the intermediate compound 7. Then the ethoxyl group was substituted with different bridge ring amines to provide the final products **1a-1f**.

The synthesis of target compounds **2a–2h** is illustrated in Scheme 2. Compounds **8a–8d** with different electronwithdrawing groups were used as starting materials. Compounds **2a–2d** were afforded *via* a 2-step nucleophilic substitution reaction with 3,4-dialkoxycyclobut-3-ene-1,2-dione and bridge-ring amines, respectively. The acyl chloride compound **4** was treated with different amines to provide amide compounds **10a–10c**, and these nitryl containing intermediates were subsequently reduced to provide compounds **11a–11c**. Compounds **11a–11c** underwent a nucleophilic substitution reaction with 3,4-diethoxycyclobut-3-ene-1,2-dione to provide compounds **12a–12c**. In the presence of bicyclo[2.2.1]heptan-2amine, the target compounds **2e–2g** were formed. The protecting group (–Boc) of compound **2g** was easily removed using HCl saturated ethyl acetate to afford the target compound **2h**.

#### 2.2 In vitro CXCR1 and CXCR2 antagonistic activity

As listed in Table 1, different bridge ring substituents were explored. Among these compounds, the bridge ring space size was found to be important for the corresponding CXCR2 affinities. When the polycyclic hydrocarbon scaffolds were enlarged (**1b**,  $^{CXCR2}IC_{50} > 100 \ \mu$ M; **1c**,  $^{CXCR2}IC_{50} = 5.5 \ \mu$ M; **1d**,



Scheme 1 Synthetic route of compounds 1a–1f. (a) SOCl<sub>2</sub>, dichloromethane; (b) dimethylamine hydrochloride, TEA, dichloromethane; (c) Pd/C, H<sub>2</sub>, methanol; (d) 3,4-diethoxycyclobut-3-ene-1,2-dione, ethanol; (e) diverse bridge ring amines, ethanol.

 $^{\rm CXCR2}IC_{50}$  = 1  $\mu M)$  or moved away from the parent nucleus (1e,  $^{\rm CXCR2}IC_{50}$  = 2.6  $\mu M$ ; 1f,  $^{\rm CXCR2}IC_{50}$  = 23.6  $\mu M$ ), the CXCR2 binding affinity of the corresponding analogues decreased dramatically.

Subsequent structure–activity relationship (SAR) determinations resulted in changing the electron-withdrawing group on the left side of the structure. Throughout our assay, the introduction of an electron-donating methyl group (2a,  $^{CXCR2}IC_{50} = 3.8 \ \mu$ M) or an electron-withdrawing cyano group (2b,  $^{CXCR2}IC_{50} = 0.45 \ \mu$ M) at the R<sub>2</sub> position resulted in loss of activity. Compared to compound 1a, after replacement of the R<sub>1</sub> amide moiety with sulfone (2c,  $^{CXCR2}IC_{50} = 0.12 \ \mu$ M) or sulfoxide (2d,  $^{CXCR2}IC_{50} = 92 \ n$ M), compound 2c exhibited a similar selectivity but weaker binding affinity and compound 2d demonstrated a suitable CXCR2 antagonistic activity but with reduced selectivity. On the basis of this observation, subsequent modifications focused on the modification of the R<sub>1</sub> amide

moiety. Compound **2e** showed an increased CXCR2 binding affinity ( $^{CXCR2}IC_{50} = 48$  nM), but a decreased selectivity ratio. When the amide along with the five-membered ring in **2e** was enlarged to a six-membered ring (**2f**,  $^{CXCR2}IC_{50} = 0.42 \mu$ M), the CXCR2 antagonistic affinity was found to be reduced approximately 10-fold. Comparing compound **2g** ( $^{CXCR1}IC_{50} = 5.6 \mu$ M and  $^{CXCR2}IC_{50} = 0.42 \mu$ M) and **2h** ( $^{CXCR1}IC_{50} > 100 \mu$ M and  $^{CXCR2}IC_{50} = 0.53 \mu$ M), the introduction of a hydrophilic center to the left-hand amide moiety (**2h**) led to a significant loss of CXCR1 antagonistic activity, resulting in an increased CXCR2 antagonistic selectivity (>188-fold) (Table 2).

#### 2.3 Cell migration suppression by compound 2e

The highly metastatic CFPAC1 pancreatic cancer cell line was selected for the following *in vitro* biological evaluation. The



Scheme 2 Synthetic route of compounds 2a-2h. (a) 3,4-diethoxycyclobut-3-ene-1,2-dione or 3,4-dimethoxycyclobut-3-ene-1,2-dione, ethanol; (b) (15,4*R*)-bicyclo[2.2.1]heptan-2-amine, ethanol or methanol; (c) diverse amines, dichloromethane; (d) Pd/C, H<sub>2</sub>, methanol; (e) HCl saturated ethyl acetate.

 Table 1
 Antagonistic activity and selectivity of bridge ring substituents

 on CXCR1/2
 binding

**RSC** Advances

		CXCR1 (µM)		CXCR2 (µM)		
No.	R <sub>1</sub>	$IC_{50}$	SEM	$IC_{50}$	SEM	Ratio <sup>a</sup>
1a	2	7.0	2.9	0.062	0.028	113
1b	- Star Boc	>100	_	>100	_	_
1c	2	35.6	3.0	5.5	0.5	6.5
1d	La contraction of the second s	6.7	0.1	1.0	0.2	6.7
1e		30.8	4.8	2.6	1.2	11.8
1f		48.8	6.5	23.6	1.2	2.1
<sup><i>a</i></sup> Ratio = $^{\text{CXCR1}}\text{IC}_{50}/^{\text{CXCR2}}\text{IC}_{50}$ .						

migration inhibitory effect of compound **2e** was studied based on a well-established wound healing assay and Transwell assay. At first, the cytotoxicity of compound **2e** was evaluated to provide a suitable concentration range for the cell migration assays. As shown in Fig. 3(A), the result indicated that compound **2e** displayed no inhibitory effect on the CFPAC1 cell line at different concentrations (6.25, 12.5, 25, 50, and 100  $\mu$ M).

Based on the cytotoxicity result, the cells were treated with 10  $\mu$ M compound **2e**. As a result, the wound area showed a timedependent decrease in healing rate and the migration inhibitory rate was 20.2% after 48 h of treatment (Fig. 3(B)). To further address the anti-cancer metastatic effect of compound **2e**, a subsequent Transwell assay was carried out. As shown in Fig. 3(C), 3 different visual fields were chosen randomly to take the count of the number of cells. The dosing group (727  $\pm$  50 cells) traversed much less into the lower chamber of the Transwell than the control group (1221  $\pm$  57 cells). Therefore, it is believed that compound **2e** may modulate the migration capacity of CFPAC1 cells *in vitro*.

#### 2.4 In vitro metabolism stability assays of compound 2e

In order to evaluate the druggability of compound **2e**, the *in vitro* stability was tested. **2e** was incubated with simulated intestinal fluid (SIF) and simulated gastric fluid (SGF), rat and human plasma, and rat and human liver microsomes. The relative concentration changes are shown in Table 3. Compound **2e** exhibited a higher stability in SGF than in SIF after 45 min of treatment. In addition, **2e** showed extreme stability in both rat and human plasma, as both stability rates

Table 2	Antagonistic	activity	and	selectivity	of	left-hand	substitu	ents
on CXCF	R1/2 binding							

	$R_2 \rightarrow O \rightarrow $						
			CXCR1 (µM)		CXCR2 (µM)		
No.	R <sub>1</sub>	$R_2$	IC <sub>50</sub>	SEM	$IC_{50}$	SEM	Ratio <sup>a</sup>
2a 2b	H H	CH <sub>3</sub> CN	86.1 42.7	2.7 1.5	3.8 0.45	1.3 0.14	22.7 94.9
2c		Cl	12.4	4.3	0.12	0.025	103.3
2d	°s'i'i	Cl	6.5	3.0	0.092	0.019	70.7
2e		Н	2.9	0.3	0.048	0.0075	60.4
2f	N y str	н	10.3	5.6	0.59	0.061	17.5
2g	Boc N N Jozz	Н	5.6	1.5	0.42	0.054	13.3
2h	HCI HN N V	н	>100	_	0.53	0.17	>188.7

<sup>*a*</sup> Ratio =  $^{\text{CXCR1}}\text{IC}_{50}/^{\text{CXCR2}}\text{IC}_{50}$ 

were >99% after 45 min. However, in liver microsome assays, compound **2e** was found to degrade at various levels. After 45 min of incubation, 84% of the compound was determined to remain in rat liver microsomes and 27% was found to remain in human liver microsomes. Therefore, improving the liver microsome stability of compound **2e** remains a critical goal that is currently being addressed in our laboratory.



**Fig. 3** (A) The survival rate of compound **2e** against the CFPAC1 cell line; (B) the images of CFPAC1 cell migration; (C) the images of the Transwell assay.

Table 3 The results of in vitro stability assays (@45 min)

	Remaining percentage (%)								
	SIF and SGF stability		Plasma stability		Liver microsome stability				
Compound	SIF	SGF	Rat	Human	Rat	Human			
2e	$92.2\pm2.0$	>99	>99	>99	$84.2 \pm 3.4$	27.4 ± 4.3			

#### 2.5 Oral pharmacokinetic profiles of compound 2e

Compound **2e** was also tested in *in vivo* pharmacokinetic studies in rats (10 mg kg<sup>-1</sup> PO). As shown in Table 4, the compound demonstrated a moderate clearance rate with a  $t_{1/2}$  of 2.58 h along with an excellent absorbance ( $C_{\text{max}}$  of 2863 ng mL<sup>-1</sup>). The mean residence time (MRT) is 3.43 h and the area under the curve from 0 h to 24 h (AUC<sub>0-t</sub>) is 8820 h ng mL<sup>-1</sup>. This preliminary data suggests that this compound may constitute a reasonable starting point for further drug development.

#### 2.6 Molecular docking

In order to give a structural illustration for the experimental results above, molecular docking was performed to further explore the mechanism of the newly developed  $N_iN'$ -diary-lsquaramide derivatives and predict the preponderant configuration of compound **2e**. Due to the absence of a crystal structure of CXCR2, the structure of CXCR1 was employed, which shares a 77% sequence similarity. The homologous modelling and docking were performed with the modules Align Sequence to Templates, Build Homology Models, Standard Dynamic Cascade and Flexible Docking (see Fig. S1<sup>†</sup>) implanted in Discovery Studio 2.5.

According to the possible ligand binding site reported previously,<sup>27</sup> the result of the docking study showed that the *S* configuration ((*S*)-2e, LibDockScore = 73.34) performed better than the *R* configuration ((*R*)-2e, LibDockScore = 52.10). As shown in Fig. 4(A), one of the ketone oxygens on the cyclobut-3-ene-1,2-dione part of (*R*)-2e is hydrogen-bonded to Arg80, and the bicyclo[2.2.1]heptane moiety of (*R*)-2e inserted into a hydrophobic pocket surrounded by Ser81, Ala249 and Val252.

Table 4         PK profiles of compound 2e	
PK parameters	Value
Dose	$10 \text{ mg kg}^{-1}$
K <sub>el</sub>	$0.285 \pm 0.084 \ \mathrm{h^{-1}}$
$t_{1/2}$	$2.58\pm0.74~\mathrm{h}$
t <sub>max</sub>	$0.33\pm0.14~\mathrm{h}$
C <sub>max</sub>	$2863 \pm 94 \text{ ng mL}^{-1}$
AUC <sub>0-t</sub>	$8820 \pm 3555 \text{ h ng mL}^{-1}$
AUC <sub>0-inf</sub>	$8940 \pm 3455 \text{ h ng mL}^{-1}$
AUMC <sub>0-t</sub>	$30~509 \pm 19~743~{\rm h}~{\rm h}~{\rm ng}~{\rm mL}^{-1}$
AUMC <sub>0-inf</sub>	$32~103 \pm 18~610~h~h~ng~mL^{-1}$
MRT <sub>PO</sub>	$3.43\pm0.73~\mathrm{h}$



Fig. 4 (A) Interaction mode of CXCR2 and (*R*)-2e; (B) interaction mode of CXCR2 and (*S*)-2e.

In contrast, (S)-2e exhibited a stronger binding mode. Interestingly, both of the ketone oxygens on the cyclobut-3-ene-1,2dione part of (S)-2e are hydrogen-bonded to Arg80, and the amino groups on the cyclobut-3-ene-1,2-dione part of (S)-2e formed additional H-bonds with Tyr314 and Gly244. The bicyclo [2.2.1]heptane moiety of (S)-2e inserted into the same hydrophobic pocket surrounded by Ser81, Ala249 and Val252. Therefore, the antagonistic activity of (S)-2e may be better than that of (R)-2e, although this needs further biological verification.

## 3. Conclusions

In conclusion, a bridged ring system was applied and explored in the N,N'-diarylsquaramide skeleton. Upon optimization, compound **2e** bearing bicyclo[2.2.1]heptane demonstrated good CXCR2 antagonistic activity and a suitable selectivity against CXCR1. In addition, good *in vitro* stability, reasonable oral pharmacokinetic profiles and a high anticancer metastatic effect were also demonstrated. Computational docking results illustrated the interaction mode of **2e**, and **(S)-2e** may demonstrate better antagonistic activity. Further chiral resolution and *in vivo* biological tests of compound **2e** are currently underway in our laboratory.

### 4. Experimental section

#### 4.1 CXCR1 and CXCR2 antagonistic activity assay

Human Embryonic Kidney 293 (HEK293) cells stably expressing G $\alpha$ 16 and CXCR1 or CXCR2 were seeded onto 96-well plates and incubated for 24 h. Cells were loaded with 2 µmol L<sup>-1</sup> Fluo-4 AM in Hanks balanced salt solution (HBSS, containing KCl 5.4 mmol L<sup>-1</sup>, Na<sub>2</sub>HPO<sub>4</sub> 0.3 mmol L<sup>-1</sup>, KH<sub>2</sub>PO<sub>4</sub> 0.4 mmol L<sup>-1</sup>, NaHCO<sub>3</sub> 4.2 mmol L<sup>-1</sup>, CaCl<sub>2</sub> 1.3 mmol L<sup>-1</sup>, MgCl<sub>2</sub> 0.5 mmol L<sup>-1</sup>, Mg<sub>2</sub>SO<sub>4</sub> 0.6 mmol L<sup>-1</sup>, NaCl 137 mmol L<sup>-1</sup>, BSA 5 g L<sup>-1</sup>, glucose 5.6 mmol L<sup>-1</sup>, and sulfinpyrazone 250 µmol L<sup>-1</sup>, at pH 7.4) at 37 °C for 45 min. The excess dye was removed and 50 µL of the HBSS containing test compounds was added. After incubation at room temperature for 10 min, 25 µL HBSS containing IL-8 was dispensed into the well using a FlexStation II microplate reader (Molecular Devices, Sunnyvale, CA, USA) and the intracellular calcium change was recorded with an excitation wavelength of 485 nm and emission wavelength of 525 nm. The

Paper

half maximal inhibitory concentrations ( $IC_{50}$ ) of compounds were determined using the "Analyze Data" "XY analyses" "Nonlinear regression (curve fit)" protocol implanted in GraphPad Prism software by constructing their dose–response curves, where the *x* axis is the log value of concentration and the *y* axis is the response value (for the curves of each compound, see Table S1†). Each experiment was repeated at least three times.

#### 4.2 Anti-proliferation assay

CFPAC1 cells were seeded in 96-well plates at a density of 4000 cells per well. After 24 h of adherence, cells were incubated with the medium alone or with medium containing test compounds for 72 h. Five different concentrations (6.25, 12.5, 25, 50, and 100  $\mu$ M) of both antagonists were used. The cell viability was determined using MTT assays. The growth inhibition was calculated as % =  $[1 - (A/B)] \times 100$ , where *A* and *B* were the absorbances of the treated and untreated cells, respectively.

#### 4.3 Cell migration assay

The cell migration assay was performed in a 24-well Transwell plate with an 8  $\mu$ m polycarbonate sterile membrane (Corning Incorporated). The cells were plated in the upper chamber at 2  $\times$  10<sup>4</sup> cells per insert in 200  $\mu$ L of serum-free medium. Inserts were placed in wells containing 600  $\mu$ L of medium supplemented with 10% FBS. After being cultured for 24 h, cells on the upper surface were detached with a cotton swab. Filters were fixed and cells in the lower filter were stained with 0.1% crystal violet for 15 minutes and photographed under a 100 $\times$  microscope. 3 different visual fields were chosen randomly to take the count of the number of cells.

#### 4.4 Wound healing assay

CFPAC1 cells (5 × 10<sup>5</sup> cells per well) were seeded in a 6-well tissue culture plate and grown to 90% confluence. After the medium was removed, a gap with constant width was created in the center of the well by scratching the monolayer with a sterile micropipette tip. The cells were then rinsed with phosphatebuffered saline (PBS) thrice to remove cellular debris, and were subsequently exposed to 1% DMSO or 10  $\mu$ M compound **2e**. The wound closure was monitored and photographed at 0, 24, and 48 h using ImagePro software. The cell migration inhibitory rate was calculated as % = [1 - (0 h wound area - 24 h or 48 h wound area)/0 h wound area] × 100.

#### 4.5 Pharmacokinetic studies

This study was performed in strict accordance with the Laboratory Animal Management Regulations (State Scientific and Technological Commission Publication No. 8-27 Rev. 2017) and was approved by Zhejiang University Laboratory Animal Center (Hangzhou, China). SD rats (purchased from Zhaoyan (Suzhou, China) New Drug Research Center Co. Ltd) were administered compound **2e** at doses of 10 mg kg<sup>-1</sup> by oral gavage in the solvent (2% DMSO + 98% (0.5% MC)). Venous blood (100  $\mu$ L) samples were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h.

#### 4.6 SIF and SGF stability assays

SIF was prepared by dissolving 0.68 grams of pancreatin (Sigma) in 100 mL of 50 mM potassium phosphate buffer (pH 7.4). SGF was prepared by dissolving 3.2 g of pepsin (Sigma) in 1000 mL water containing 2.0 g of sodium chloride (Sinopharm Chemical Reagent Co., Ltd) and 7.0 mL of concentrated hydrochloric acid (Sinopharm Chemical Reagent Co., Ltd) (pH about 1.2). A 480 µL aliquot of the SIF buffer or SGF solution was added to 20  $\mu$ L of a test article solution at 100  $\mu$ g mL<sup>-1</sup> to give a final solution. The mixture was incubated at 37 °C with gentle agitation. An aliquot of 100 µL of the reaction mixture was taken at 0, 15, and 45 minutes and quenched using 400 µL of methanol containing 1  $\mu$ g mL<sup>-1</sup> internal standard compound (from the in-house database). After quenching, the mixture was vortexed and centrifuged and 10 µL of the resulting solution was injected into a Shimadzu LCMS-2020 system. The percentage remaining of the test article at the incubation times of 15 and 45 minutes relative to that at 0 minutes was calculated using the peak area ratio of the test article versus the internal standard.

Plasma was separated from whole blood by centrifugation and

stored at -20 °C until analysis. Compound levels were deter-

mined using an Agilent 1200-API4000QTRAP LC/MS system.

#### 4.7 Plasma stability assay

A 500  $\mu$ L aliquot of rat plasma or human plasma (purchased from Shanghai Yuduo Biotechnology Company) was added to 5  $\mu$ L of a test article solution at 100  $\mu$ g mL<sup>-1</sup> to give a final solution. The mixture was incubated at 37 °C with gentle agitation. An aliquot of 100  $\mu$ L of the reaction mixture was taken at 0, 15, and 45 minutes and quenched using 400  $\mu$ L of methanol containing 1  $\mu$ g mL<sup>-1</sup> internal standard compound (from the in-house database). After quenching, the mixture was injected into an API4000 + LC/MS system. The percentage remaining of the test article at the incubation times of 15 and 45 minutes relative to that at 0 minutes was calculated using the peak area ratio of the test article *versus* the internal standard.

#### 4.8 Liver microsome stability assay

1 mg mL<sup>-1</sup> microsome solution (purchased from Ruide Research Institute for Liver Diseases (Shanghai) Co. Ltd) was mixed with 20  $\mu$ L of 50 mM NADPH (Aladdin) solution to prepare a microsome-NADPH solution. 500  $\mu$ L of the microsome-NADPH solution was pre-warmed at 37 °C for 5 minutes. 5  $\mu$ L of a 100  $\mu$ g mL<sup>-1</sup> test article solution was then added to initiate the reaction. The incubation mixture was kept at 37 °C and 100  $\mu$ L aliquots were taken at 0, 15, and 45 minutes. In each aliquot, the reaction was quenched using 400  $\mu$ L of methanol containing 1  $\mu$ g mL<sup>-1</sup> internal standard compound (from the in-house database). After quenching, the mixtures were vortexed and centrifuged. The supernatant was transferred and 10  $\mu$ L was injected into an API4000 + LC/MS system. The peak area ratio of a test article *versus* the internal standard was

#### 4.9 Chemistry

**4.9.1 General experimental information.** All reagents and solvents were used as purchased from commercial sources. Chromatography was performed using silica gel (200–300 mesh) or a C18 column. All reactions were monitored by TLC, using silica gel plates with fluorescence F254 and UV light visualization. Proton NMR spectra were obtained on a Bruker AVII 500 spectrometer with the use of CDCl<sub>3</sub>, CD<sub>3</sub>OD, (CD<sub>3</sub>)<sub>2</sub>CO or DMSO-d6 as the solvent. Carbon-13 NMR spectra were obtained on a Bruker spectrometer (125 MHz) using DMSO-d6 as the solvent. Chemical shifts are referenced to the residual solvent peak and reported in ppm (*d* scale) and all coupling constant (*J*) values are given in Hz. The following multiplicity abbreviations are used: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) multiplet, and (br) broad. ESI-MS data were recorded on a Shimadzu LC-MS 2020 instrument.

**4.9.2 3-((2-Ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-***N,N***-dimethylbenzamide** (7). 2-Hydroxy-3-nitrobenzoic acid (compound 3, 5 g) was added to thionyl chloride (5 mL) and heated under reflux for 12 h. The solution was concentrated to afford 2-hydroxy-3-nitrobenzoyl chloride (compound 4, 4.6 g), which can be used directly for the next step. To a solution of 4 (4 g, 20 mmol) and TEA (8 g, 80 mmol) in DCM, dimethylamine hydrochloride (3.3 g, 40 mmol) was added, then the solution was stirred for 6 h at room temperature. The solution was extracted with 1 N NaOH (20 mL × 3), the aqueous phase was combined and acidized to pH = 1–2 with 1 N HCl, then extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to afford compound 5 (3.6 g).

To a solution of compound 5 (105 mg, 0.5 mmol) in methanol, Pd/C (10 mg) was added and then heated under reflux for 6 h under a H<sub>2</sub> atmosphere. The solution was filtered and the filtrate was concentrated to afford compound 6, which needed to be used directly for the next step. To a solution of compound 6 in ethanol, 3,4-diethoxycyclobut-3-ene-1,2-dione (128 mg, 0.75 mmol) was added and the solution was stirred for 12 h at room temperature. The solution was concentrated, the residue was dissolved in water and acidized to pH = 1-2with 1 N HCl, then extracted with EtOAc (50 mL  $\times$  3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, then filtered and concentrated. The residue was purified using silica gel chromatography to afford compound 7 (96 mg, 63% total yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz,  $CDCl_3$ )  $\delta$  7.79 (s, 1H), 7.12 (m, 1H), 6.90 (t, J = 8.0 Hz, 1H), 4.88 (m, 2H), 3.20 (s, 6H), 1.53 (t, J = 7.0 Hz, 3H). ESI-MS: m/z = 303 $[M-H]^+$ .

**4.9.3 General procedure A for preparation of 3-((bridge ring-yl)amino)-2-hydroxy-***N*,*N*-**dimethylbenzamide (1a-1e).** To a solution of compound 7 (0.2 mmol) in ethanol, bridge ring amine (0.3 mmol) was added, then stirred at room temperature for 12 h. The solution was acidized to pH = 3-4 with 1 N HCl and then concentrated. The residue was purified using C18

chromatography (eluent: MeOH :  $H_2O=1:4\mathchar`-1:1)$  to afford compound  $1a\mathchar`-1e.$ 

4.9.4 3-((2-(((1*S*,4*R*)-Bicyclo[2.2.1]heptan-2-yl)amino)-3,4dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-*N*,*N*-dimethylbenzamide (1a). General procedure A, yield: 47%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.97 (s, 1H), 6.99 (m, 1H), 6.94 (m, 1H), 4.29 (m, 1H), 3.08 (s, 6H), 2.49–2.25 (m, 2H), 2.22–1.87 (m, 1H), 1.69 (m, 1H), 1.54 (m, 2H), 1.44 (m, 1H), 1.32 (m, 2H), 1.24–0.95 (m, 1H). ESI-MS:  $m/z = 368 \text{ [M-H]}^+$ .

4.9.5 *Tert*-butyl (1*R*,5*S*)-3-((2-((3-(dimethylcarbamoyl)-2-hydroxyphenyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (1b). General procedure A, yield: 43%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.89 (s, 1H), 6.98 (m, 2H), 4.23 (m, 2H), 3.15–3.00 (m, 6H), 2.32 (s, 1H), 2.08–1.83 (m, 8H), 1.48 (s, 9H). ESI-MS:  $m/z = 483 \text{ [M-H]}^+$ .

4.9.6 3-((3,4-Dioxo-2-(((1*R*,4*R*)-1,7,7-trimethylbicyclo[2.2.1] heptan-2-yl)amino)cyclobut-1-en-1-yl)amino)-2-hydroxy-*N*,*N*-dimethylbenzamide (1c). General procedure A, yield: 32%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.91 (m, 1H), 6.99 (m), 6.94 (m, 1H), 3.08 (s, 6H), 1.98 (m, 1H), 1.86–1.76 (m, 3H), 1.64 (m, 1H), 1.35–1.18 (m, 3H), 1.01 (s, 3H), 0.91 (m, 6H). ESI-MS: *m*/*z* = 410 [M-H]<sup>+</sup>.

4.9.7 2-Hydroxy-*N*,*N*-dimethyl-3-((2-(((4*R*,7*R*,7*aR*)-octahydro-1*H*-4,7-methanoinden-5-yl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide (1d). General procedure A, yield: 26%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.84 (s, 1H), 6.89 (d, *J* = 6.9 Hz, 1H), 6.77 (t, *J* = 7.6 Hz, 1H), 3.09 (s, 6H), 2.24–2.18 (m, 1H), 2.08 (m, 1H), 2.01–1.78 (m, 4H), 1.77–1.70 (m, 1H), 1.61 (m, 1H), 1.44– 1.24 (m, 2H), 1.19–1.04 (m, 2H), 0.99–0.76 (m, 3H). ESI-MS: *m*/ *z* = 408 [M–H]<sup>+</sup>.

4.9.8 3-((2-((((1*S*,4*S*)-Bicyclo[2.2.1]hept-5-en-2-yl)methyl) amino)-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-*N*,*N*-dimethylbenzamide (1e). General procedure A, yield: 39%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) *d* 7.88 (m, 1H), 6.93–6.83 (m, 1H), 6.77 (m, 1H), 6.15–5.76 (m, 2H), 3.69–3.50 (m, 1H), 3.30–3.13 (m, 1H), 3.02 (d, J = 5.5 Hz, 6H), 2.82–2.52 (m, 2H), 1.84–1.70 (m, 1H), 1.62–1.04 (m, 4H). ESI-MS: m/z = 380 [M–H]<sup>+</sup>.

4.9.9 3-((2-((((1*R*,4*S*)-Bicyclo[2.2.1]heptan-2-yl)methyl) amino)-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-*N*,*N*-dimethylbenzamide (1f). General procedure A, yield: 30%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.73 (m, 1H), 6.82 (m, 1H), 6.71 (m, 1H), 3.02 (m, 6H), 2.28–1.99 (m, 4H), 1.72 (m, 1H), 1.51–1.45 (m, 2H), 1.30 (m, 2H), 1.13–1.01 (m, 3H), 0.74–0.63 (m, 1H). ESI-MS:  $m/z = 382 \text{ [M-H]}^+$ .

4.9.10 General procedure B for preparation of 3-(substituted amino)-4-ethoxycyclobut-3-ene-1,2-dione (9a and 9b) or 3-(substituted amino)-4-methoxycyclobut-3-ene-1,2dione (9c and 9d). To a solution of substituted aminophenol 8a-8d (0.5 mmol) in ethanol, 3,4-diethoxycyclobut-3-ene-1,2dione (128 mg, 0.75 mmol) or 3,4-dimethoxycyclobut-3-ene-1,2dione (107 mg, 0.75 mmol) was added, and stirred for 12 h at room temperature. The solution was concentrated, the residue was dissolved in water and acidized to pH = 1-2 with 1 N HCl, and then extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, then filtered and concentrated. The residue was purified using silica gel chromatography to afford compounds 9a-9d. **4.9.11** 3-Ethoxy-4-((2-hydroxy-4-methylphenyl)amino) cyclobut-3-ene-1,2-dione (9a). General procedure B, yield: 70%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.33 (m, 1H), 6.87 (s, 1H), 6.74 (d, J = 8.0 Hz, 1H), 4.97 (q, J = 7.0 Hz, 2H), 2.30 (s, 3H), 1.56 (t, J =7.0 Hz, 3H). ESI-MS: m/z = 246 [M-H]<sup>+</sup>.

**4.9.12 4-((2-Ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)-3-hydroxybenzonitrile (9b).** General procedure B, yield: 53%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.64 (d, *J* = 8.0 Hz, 1H), 7.22 (m, 1H), 7.12 (t, *J* = 3.0 Hz, 1H), 4.85–4.81 (m, 2H), 1.53–1.46 (m, 3H). ESI-MS: *m/z* = 257 [M–H]<sup>+</sup>.

**4.9.13 3-((4-Chloro-2-hydroxy-3-(isopropylsulfonyl)phenyl)** amino)-4-methoxycyclobut-3-ene-1,2-dione (9c). General procedure B, yield: 47%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.67 (d, J = 8.5 Hz, 1H), 7.17 (m, 1H), 4.43 (s, 3H), 3.97–3.87 (m, 1H), 1.35 (d, J = 7.0 Hz, 6H). ESI-MS: m/z = 358 [M–H]<sup>+</sup>.

**4.9.14 3-((4-Chloro-2-hydroxy-3-(isopropylsulfinyl)phenyl) amino)-4-methoxycyclobut-3-ene-1,2-dione (9d).** General procedure B, yield: 43%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  12.27 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 6.93 (d, J = 9.0 Hz, 1H), 4.51 (s, 3H), 3.41 (m, 1H), 1.44 (m, 6H). ESI-MS: m/z = 342 [M-H]<sup>+</sup>.

4.9.15 General procedure C for preparation of 3-(substituted amino)-4-ethoxycyclobut-3-ene-1,2-dione (12a– 12c). To a solution of 4 (2 mmol) and TEA (4 mmol) in DCM, amine (2 mmol) was added, then stirred for 6 h at room temperature. The solution was extracted with 1 N NaOH (20 mL  $\times$  3), the aqueous phase was combined and acidized to pH = 1– 2 with 1 N HCl, then extracted with EtOAc (50 mL  $\times$  3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to afford compound 10a–10c.

To a solution of compound **10a–10c** in methanol, Pd/C was added, then heated under reflux for 6 h under a H<sub>2</sub> atmosphere. The solution was filtered and the filtrate was concentrated to afford compounds **11a–11c**, which needed to be used directly for the next step. To a solution of **11a–11c** in ethanol, 3,4-diethoxycyclobut-3-ene-1,2-dione was added, and the solution was stirred for 12 h at room temperature. The solution was concentrated, the residue was dissolved in water and acidized to pH = 1–2 with 1 N HCl, then extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, then filtered and concentrated. The residue was purified using silica gel chromatography to afford compounds **12a–12c**.

**4.9.16 3-Ethoxy-4-((2-hydroxy-3-(pyrrolidine-1-carbonyl)** phenyl)amino)cyclobut-3-ene-1,2-dione (12a). General procedure C, yield: 57%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) *d* 7.82 (s, 1H), 7.30–7.27 (m, 1H), 6.89 (m, 1H), 4.88 (q, J = 7.0 Hz, 2H), 3.74 (s, 4H), 2.02–1.93 (m, 4H), 1.58–1.47 (m, 3H). ESI-MS: m/z = 329[M–H]<sup>+</sup>.

**4.9.17 3-Ethoxy-4-((2-hydroxy-3-(piperidine-1-carbonyl)** phenyl)amino)cyclobut-3-ene-1,2-dione (12b). General procedure C, yield: 31%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.80 (s, 1H), 7.02 (m, 1H), 6.88 (m, 1H), 4.88 (q, *J* = 7.0 Hz, 2H), 3.70–3.63 (m, 4H), 1.77–1.64 (m, 6H), 1.53 (t, *J* = 7.0 Hz, 3H). ESI-MS: *m*/*z* = 343 [M–H]<sup>+</sup>.

4.9.18 *Tert*-butyl 4-(3-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl) amino)-2-hydroxybenzoyl)piperazine-1-carboxylate (12c). General

procedure C, yield: 39%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.76 (s, 1H), 7.06–6.98 (m, 1H), 6.92 (t, *J* = 8.0 Hz, 1H), 4.89 (q, *J* = 7.0 Hz, 2H), 3.79–3.68 (m, 4H), 3.56–3.48 (m, 4H), 1.54 (t, *J* = 7.0 Hz, 3H), 1.48 (s, 9H). ESI-MS: *m*/*z* = 444 [M–H]<sup>+</sup>.

4.9.19 General procedure D for the preparation of 3-(((1*S*,4*R*)-bicyclo[2.2.1]heptan-2-yl)amino)-4-((substitutedphenyl)amino)cyclobut-3-ene-1,2-dione (2a-2g). To a solution of compounds 9a-9e and 12a-12c in ethanol, (1*S*,4*R*)-bicyclo[2.2.1] heptan-2-amine was added, then stirred at room temperature for 12 h. The solution was acidized to pH = 3-4 with 1 N HCl, and then concentrated. The residue was purified using C18 chromatography (eluent: MeOH :  $H_2O = 1 : 4-1 : 1$ ) to afford compounds 2a-2g.

4.9.20 3-(((1*S*,4*R*)-Bicyclo[2.2.1]heptan-2-yl)amino)-4-((2-hydroxy-4-methylphenyl)amino)cyclobut-3-ene-1,2-dione (2a). General procedure D, yield: 48%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.75 (m, 1H), 6.66 (m, 2H), 4.56–4.04 (m, 1H), 2.42 (m, 1H), 2.34–2.28 (m, 1H), 2.26 (s, 3H), 2.23–1.87 (m, 1H), 1.78–1.66 (m, 1H), 1.65–1.36 (m, 4H), 1.31 (m, 1H), 1.25–0.96 (m, 1H). ESI-MS:  $m/z = 311 \text{ [M-H]}^+$ .

4.9.21 4-((2-(((1*S*,4*R*)-Bicyclo[2.2.1]heptan-2-yl)amino)-3,4dioxocyclobut-1-en-1-yl)amino)-3-hydroxybenzonitrile (2b). General procedure D, yield: 40%. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.06 (s, 1H), 9.45 (m, 1H), 8.48 (m, 1H), 8.06 (t, J = 9.0 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.16 (m, 1H), 4.40 (m, 1H), 2.34 (m, 1H), 2.24 (s, 1H), 2.14–1.81 (m, 1H), 1.69–1.56 (m, 1H), 1.55–1.27 (m, 4H), 1.25–1.17 (m, 1H), 1.16–0.92 (m, 1H). ESI-MS: m/z =322 [M–H]<sup>+</sup>.

**4.9.22** 3-(((1*S*,4*R*)-Bicyclo[2.2.1]heptan-2-yl)amino)-4-((4chloro-2-hydroxy-3-(isopropylsulfonyl)phenyl)amino)cyclobut-3-ene-1,2-dione (2c). General procedure D, yield: 27%. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  9.39 (m, 1H), 8.50 (m, 1H), 7.75 (m, 1H), 6.06 (s, 1H), 4.41 (m, 2H), 2.32–2.28 (m, 1H), 2.21 (m, 1H), 2.07– 1.92 (m, 1H), 1.66 (m, 1H), 1.50 (d, J = 5.5 Hz, 1H), 1.43 (d, J = 9.0 Hz, 2H), 1.32 (d, J = 8.5 Hz, 2H), 1.14–1.11 (m, 6H), 0.96 (m, 1H). ESI-MS: m/z = 437 [M–H]<sup>+</sup>.

**4.9.23 3-(((15,4***R***)-Bicyclo[2.2.1]heptan-2-yl)amino)-4-((4chloro-2-hydroxy-3-(isopropylsulfinyl)phenyl)amino)cyclobut-3ene-1,2-dione (2d).** General procedure D, yield: 31%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  9.29 (m, 1H), 8.31 (m, 1H), 8.01 (t, *J* = 8.5 Hz, 1H), 7.08 (d, *J* = 8.5 Hz, 1H), 4.38 (s, 1H), 3.51 (s, 1H), 2.33 (m, 1H), 2.23 (s, 1H), 2.09 (m, 1H), 1.69–1.55 (m, 1H), 1.55–1.42 (m, 2H), 1.40–1.28 (m, 8H), 1.26–1.11 (m, 2H). ESI-MS: *m*/*z* = 421 [M–H]<sup>+</sup>.

**4.9.24 3-(((15,4***R***)-Bicyclo[2.2.1]heptan-2-yl)amino)-4-((2-hydroxy-3-(pyrrolidine-1-carbonyl)phenyl)amino)cyclobut-3ene-1,2-dione (2e).** General procedure D, yield: 38%. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  8.36 (m, 1H), 7.91–7.82 (m, 1H), 7.15–7.09 (m, 1H), 6.87 (t, *J* = 8.0 Hz, 1H), 4.18 (m, 1H), 3.57–3.48 (m, 4H), 2.34 (m, 1H), 2.24 (s, 1H), 2.09 (s, 1H), 1.91–1.75 (m, 4H), 1.73–1.56 (m, 1H), 1.55–1.30 (m, 4H), 1.17 (m, 1H), 0.98 (m, 1H). <sup>13</sup>C NMR (126 MHz, DMSO)  $\delta$  184.70, 180.68, 169.75, 168.48, 163.88, 163.68, 122.68, 122.57, 122.09, 121.91, 121.62, 119.01, 57.27, 55.49, 44.00, 42.69, 38.14, 37.66, 36.91, 35.75, 35.20, 30.03, 28.26, 26.11, 21.18. ESI-MS: *m*/*z* = 394 [M–H]<sup>+</sup>.

4.9.25 3-(((1*S*,4*R*)-Bicyclo[2.2.1]heptan-2-yl)amino)-4-((2-hydroxy-3-(piperidine-1-carbonyl)phenyl)amino)cyclobut-3-ene-

**1,2-dione (2f).** General procedure D, yield: 26%. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  8.48–8.29 (m, 1H), 7.82–7.70 (m, 1H), 6.78 (s, 1H), 4.38 (s, 1H), 3.40 (s, 4H), 2.32 (m, 1H), 2.19 (m, 2H), 2.09 (m, 1H), 1.79 (m, 1H), 1.70–1.63 (m, 1H), 1.58 (s, 2H), 1.44 (m, 4H), 1.23 (m, 3H), 0.79 (m, 1H). ESI-MS:  $m/z = 408 \text{ [M-H]}^+$ .

4.9.26 *Tert*-butyl 4-(3-(((15,4*R*)-bicyclo[2.2.1]heptan-2-yl) amino)-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxybenzoyl) piperazine-1-carboxylate (2g). General procedure D, yield: 42%. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.99 (s, 1H), 7.04–6.94 (m, 2H), 4.32 (m, 1H), 3.57 (m, 8H), 2.43 (m, 1H), 2.36–2.29 (m, 1H), 2.26–1.89 (m, 1H), 1.73 (m, 1H), 1.66–1.53 (m, 3H), 1.49 (s, 10H), 1.33 (m, 1H), 1.13 (m, 1H). ESI-MS:  $m/z = 509 [M-H]^+$ .

4.9.27 3-(((1*S*,4*R*)-Bicyclo[2.2.1]heptan-2-yl)amino)-4-((2-hydroxy-3-(piperazine-1-carbonyl)phenyl)amino)cyclobut-3-ene-1,2-dione hydrochloride (2h). To a solution of compound 2g (51 mg, 0.1 mmol) in methanol, HCl in ethyl acetate was added, and the solution was stirred for 12 h at room temperature. The solution was concentrated and the residue was washed with dry ethyl acetate to afford compound 2h (38 mg, yield 85%) as a light yellow solid. <sup>1</sup>H NMR (500 MHz, MeOD)  $\delta$  7.89 (s, 1H), 7.03 (m, 1H), 6.98 (m, 1H), 4.49 (m, 1H), 3.86 (s, 4H), 2.41 (m, 1H), 2.33–2.27 (m, 1H), 2.20 (m, 1H), 2.01 (m, 1H), 1.91 (m, 1H), 1.70 (m, 1H), 1.63–1.25 (m, 7H), 1.23–1.13 (m, 1H). ESI-MS: *m/z* = 409 [M–H]<sup>+</sup>.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We are grateful to Dr Bo Zhang (Hangzhou First People's Hospital) for assistance with the cell migration assays. This work was supported by the National Natural Science Foundation of China (Grant No.: 81673294, 81472862 and 81425024).

## References

- 1 W. E. Holmes, J. Lee, W. J. Kuang, G. C. Rice and W. I. Wood, *Science*, 1991, **253**, 1278–1280.
- 2 P. M. Murphy and H. L. Tiffany, Science, 1991, 253, 1280–1283.
- 3 J. Vandercappellen, J. Van Damme and S. Struyf, *Cancer Lett.*, 2008, **267**, 226–244.
- 4 Y. Wang, Y. Qu, X. L. Niu, W. J. Sun, X. L. Zhang and L. Z. Li, *Cytokine*, 2011, **56**, 365–375.
- 5 Y. S. Lee, I. Choi, Y. Ning, N. Y. Kim, V. Khatchadourian,
  D. Yang, H. K. Chung, D. Choi, M. J. LaBonte,
  R. D. Ladner, K. C. Nagulapalli Venkata, D. O. Rosenberg,
  N. A. Petasis, H. J. Lenz and Y. K. Hong, *Br. J. Cancer*, 2012, 106, 1833–1841.
- 6 J. K. Singh, G. Farnie, N. J. Bundred, B. M. Simoes, A. Shergill, G. Landberg, S. J. Howell and R. B. Clarke, *Clin. Cancer Res.*, 2013, **19**, 643–656.
- 7 C. W. Steele, S. A. Karim, J. D. Leach, P. Bailey, R. Upstill-Goddard, L. Rishi, M. Foth, S. Bryson, K. McDaid, Z. Wilson, C. Eberlein, J. B. Candido, M. Clarke, C. Nixon, J. Connelly, N. Jamieson, C. R. Carter, F. Balkwill, D. K. Chang, T. R. Evans, D. Strathdee, A. V. Biankin,

R. J. Nibbs, S. T. Barry, O. J. Sansom and J. P. Morton, *Cancer Cell*, 2016, **29**, 832–845.

- 8 W. L. Cheng, C. S. Wang, Y. H. Huang, M. M. Tsai, Y. Liang and K. H. Lin, *Ann. Oncol.*, 2011, **22**, 2267–2276.
- 9 A. Li, X. J. Cheng, A. Moro, R. K. Singh, O. J. Hines and G. Eibl, *Transl Oncol.*, 2011, 4, 20–28.
- 10 K. M. Hertzer, G. W. Donald and O. J. Hines, *Expert Opin. Ther. Targets*, 2013, **17**, 667–680.
- 11 B. Sharma, M. L. Varney, S. Saxena, L. Wu and R. K. Singh, *Cancer Lett.*, 2016, 372, 192–200.
- 12 J. C. Acosta and J. Gil, Cancer Res., 2009, 69, 2167-2170.
- 13 S. Singh, M. Varney and R. K. Singh, *Cancer Res.*, 2009, **69**, 411-415.
- 14 G. Yang, D. G. Rosen, G. Liu, F. Yang, X. Guo, X. Xiao, F. Xue, I. Mercado-Uribe, J. Huang, S. H. Lin, G. B. Mills and J. Liu, *Clin. Cancer Res.*, 2010, **16**, 3875–3886.
- 15 B. Devapatla, A. Sharma and S. Woo, *PLoS One*, 2015, **10**, e0139237.
- 16 B. Otvos, D. J. Silver, E. E. Mulkearns-Hubert, A. G. Alvarado, S. M. Turaga, M. D. Sorensen, P. Rayman, W. A. Flavahan, J. S. Hale, K. Stoltz, M. Sinyuk, Q. Wu, A. Jarrar, S. H. Kim, P. L. Fox, I. Nakano, J. N. Rich, R. M. Ransohoff, J. Finke, B. W. Kristensen, M. A. Vogelbaum and J. D. Lathia, *Stem Cells*, 2016, **34**, 2026–2039.
- 17 A. Purohit, M. Varney, S. Rachagani, M. M. Ouellette, S. K. Batra and R. K. Singh, *Oncotarget*, 2016, 7, 7280–7296.
- 18 I. M. Stromnes and P. D. Greenberg, *Cancer Cell*, 2016, **29**, 774–776.
- 19 X. Lu, J. W. Horner, E. Paul, X. Y. Shang, P. Troncoso, P. N. Deng, S. Jiang, Q. Chang, D. J. Spring, P. Sharma, J. A. Zebala, D. Y. Maeda, Y. A. Wang and R. A. DePinho, *Nature*, 2017, 543, 728–732.
- 20 T. P. Stockdale and C. M. Williams, *Chem. Soc. Rev.*, 2015, 44, 7737–7763.
- 21 T. H. Keller, A. Pichota and Z. Yin, *Curr. Opin. Chem. Biol.*, 2006, **10**, 357–361.
- 22 P. D. Leeson and B. Springthorpe, *Nat. Rev. Drug Discovery*, 2007, **6**, 881–890.
- 23 M. P. Gleeson, A. Hersey, D. Montanari and J. Overington, *Nat. Rev. Drug Discovery*, 2011, **10**, 197–208.
- 24 M. P. Dwyer, Y. N. Yu, J. P. Chao, C. Aki, J. H. Chao, P. Biju, V. Girijavallabhan, D. Rindgen, R. Bond, R. Mayer-Ezel, J. Jakway, R. W. Hipkin, J. Fossetta, W. Gonsiorek, H. Bian, X. D. Fan, C. Terminelli, J. Fine, D. Lundell, J. R. Merritt, L. L. Rokosz, B. Kaiser, G. Li, W. Wang, T. Stauffer, L. Ozgur, J. Baldwin and A. G. Taveras, J. Med. Chem., 2006, 49, 7603–7606.
- 25 J. R. Merritt, L. L. Rokosz, K. H. Nelson Jr, B. Kaiser, W. Wang, T. M. Stauffer, L. E. Ozgur, A. Schilling, G. Li, J. J. Baldwin, A. G. Taveras, M. P. Dwyer and J. Chao, *Bioorg. Med. Chem. Lett.*, 2006, 16, 4107–4110.
- 26 J. Chao, A. G. Taveras, J. Chao, C. Aki, M. Dwyer, Y. Yu, B. Purakkattle, D. Rindgen, J. Jakway, W. Hipkin, J. Fosetta, X. Fan, D. Lundell, J. Fine, M. Minnicozzi, J. Phillips and J. R. Merritt, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 3778–3783.
- 27 K. Salchow, M. E. Bond, S. C. Evans, N. J. Press, S. J. Charlton,
  P. A. Hunt and M. E. Bradley, *Br. J. Pharmacol.*, 2010, 159, 1429–1439.